By Tracey Cannova, Associate Medical Director, US Oncology Medical AffairsBy Tracey Cannova, Associate Medical Director, US Oncology Medical Affairs Working in medical affairs is exciting and...

Luca Dezzani is the Vice President of U.S. Medical Affairs for Eisai’s Oncology Business Group. He is responsible for Medical Affairs strategy for the company's oncology portfolio of both...

Dr. Lynn Kramer, CMO, Eisai Neurology, discusses the FDA’s regulatory pathway allowing for the extrapolation of clinical data from adjunctive to monotherapy use in partial-onset seizures, which improves access to epilepsy treatments.

Human genetics is transforming the way new drugs are discovered, giving unprecedented hope for delivering better medicines